GENOR-B (06998) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 32.245 million, representing a year-over-year increase of 122.84%. Gross profit reached RMB 32.245 million, up 128.35% compared to the same period last year.

According to the announcement, the Group has successfully achieved light asset operation as of the announcement date, effectively reducing operational costs. While implementing cost reduction and efficiency improvement measures, the Group actively pursued strategic partnerships and submitted a new listing application to the Stock Exchange regarding the proposed merger.

The Group also made significant progress in its pipeline development. The Class 1 innovative drug Lairaxeli Hydrochloride Tablets (trade name: Rujaning) received NMPA approval on May 27, 2025. The approved indications include treatment for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) locally advanced or metastatic breast cancer: in combination with aromatase inhibitors as initial endocrine therapy; and in combination with fulvestrant for patients with disease progression following prior endocrine therapy.

To advance the commercialization of Lairaxeli (GB491) and its application for inclusion in the National Medical Insurance Catalog, the Group entered into an exclusive entrustment agreement for Lairaxeli (GB491) with Yiteng Pharmaceutical. Localized production technology transfer and market launch preparations for Lairaxeli (GB491) are being conducted simultaneously.

The Phase I clinical trial application for core pipeline product GB268 (anti-PD-1/VEGF/CTLA-4 trispecific antibody) has been approved by NMPA, and the first-in-human (FIH) clinical trial has been initiated. Clinical trials for GB261 (CD20/CD3 bispecific antibody) for the treatment of autoimmune diseases have commenced in regions outside Greater China.